Novo Nordisk risk profile
31 Normal where most of the sector sits
Measured 1 September 2026 from NVO's filed statements. Recomputed nightly.
31 (Normal), driven by Operating pressure at 52, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 50 | Elevated | Volatile | One-year price volatility — 46.0% |
| Operating pressure | 52 | Elevated | Worsening | Costs outgrowing revenue — +5.5 percentage points |
| Cash conversion | 45 | Elevated | Worsening | Capital spending against operating cash — 0.76x |
| Leverage and coverage | 21 | Normal | Stable | Current ratio — 0.80x |
| Competitive position | 15 | Contained | Stable | R&D-intensity gap against peers — +2.5 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.